USA > JAPAN based Otsuka Pharmaceutical is set to acquire USA based Visterra for approximately $430 million

otsuka logo In an all cash transaction, Japan based Otsuka Pharmaceutical is set to acquire USA based Visterra Inc. for approximately $430 million. The transaction has been approved by boards of directors of both companies and the deal is subject to customary closing conditions, including expiration or termination of the waiting period under U.S. antitrust laws and is expected to close in More …

USA > Japan’s Otsuka Pharmaceutical to acquire US based Neurovance

Otsuka_Holdings_logo.svg Japan based Otsuka Pharmaceutical Company (OPC) to acquire USA based Neurovance. The acquisition of Neurovance comes with the hefty sum of $100 million and additional $150 million contingent on achievement of development and approval milestones with additional payments contingent on achievement of sales milestones set by OPC. The transaction is set to close by second quarter of 2017 but is More …